Abstract
Chronic myeloid leukaemia (CML) is a well known model of a disease refractory to chemotherapy, including anthracyclines and other drugs that are believed to be pumped out of the cells by a 170 Kd transmembrane glycoprotein (P170). In 35 cases of Ph+ CML we investigated the reactivity of leukaemic cells to a P170-directed monoclonal antibody (MRK-16), by means of flow cytometry. P170 overexpression was found in 4/14 (29%) chronic phase CML cases and in 16/23 (70%) accelerated and blastic phase CML cases (P = 0.01). The same cells were assayed for their ability to retain Daunorubicin and Idarubicin after 2-hours in vitro incubation with 1000 ng/ml of either drug. It was found that anthracycline cell concentration was negatively related with the degree of the reactivity to MRK-16. In accelerated and blastic phase, CML cells simultaneously expressed P170 and the stem cell related marker, CD34. These data confirm that Ph+ leukaemic cells overexpress P170, show that P170 overexpression is functionally relevant, and suggest that P170-related multidrug resistance may be an important factor for chemotherapy failure in Ph+ CML.
References
Jan 24, 1992·Science·K V ChinM M Gottesman
Feb 1, 1992·European Journal of Haematology·M MichieliS Pileri
Nov 1, 1992·Leukemia & Lymphoma·J P MarieR Zittoun
May 1, 1991·British Journal of Haematology·A F ListA A Sandberg
Aug 1, 1991·Histopathology·S A PileriT Tsuruo
Jul 1, 1990·British Journal of Haematology·H SatoA Gottlieb
Jul 12, 1991·Cell·P M Chaudhary, I B Roninson
Jan 1, 1990·Human Pathology·R S WeinsteinJ S Coon
Jan 1, 1990·British Journal of Haematology·Y KuwazuruS Akiyama
May 15, 1991·Journal of the National Cancer Institute·R PirkerL Havelec
Mar 7, 1990·Journal of the National Cancer Institute·N A Bruno, D L Slate
Oct 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·H Hamada, T Tsuruo
Oct 1, 1986·Scandinavian Journal of Haematology·J M Goldman
Jan 4, 1989·Journal of the National Cancer Institute·C K Luk, I F Tannock
Dec 1, 1988·British Journal of Cancer·S B Kaye
Aug 9, 1973·The New England Journal of Medicine·R D Barr, P J Fialkow
Feb 1, 1993·Leukemia & Lymphoma·M MichieliM Baccarani
Apr 1, 1993·Anti-cancer Drugs·D DamianiM Baccarani
Citations
Feb 19, 2002·British Journal of Haematology·Daniela DamianiMichele Baccarani
Mar 2, 1999·British Journal of Haematology·M MichieliM Baccarani
Sep 1, 1996·Leukemia & Lymphoma·M MichieliM Baccarani
Jun 26, 2003·Cancer Science·Motoi MukaiShin-Ichi Akiyama